| Literature DB >> 19835478 |
Jurgen Vercauteren1, Annemarie M J Wensing, David A M C van de Vijver, Jan Albert, Claudia Balotta, Osamah Hamouda, Claudia Kücherer, Daniel Struck, Jean-Claude Schmit, Birgitta Asjö, Marie Bruckova, Ricardo J Camacho, Bonaventura Clotet, Suzie Coughlan, Zehava Grossman, Andrzej Horban, Klaus Korn, Leondios Kostrikis, Claus Nielsen, Dimitrios Paraskevis, Mario Poljak, Elisabeth Puchhammer-Stöckl, Chiara Riva, Lidia Ruiz, Mika Salminen, Rob Schuurman, Anders Sonnerborg, Danica Stanekova, Maja Stanojevic, Anne-Mieke Vandamme, Charles A B Boucher.
Abstract
The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%-9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%-5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%-2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%-3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (P = .04) and in NNRTI resistance after an initial increase (P = .02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19835478 DOI： 10.1086/644505
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226